Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

6.26USD
22 Aug 2019
Change (% chg)

$-0.01 (-0.12%)
Prev Close
$6.27
Open
$6.25
Day's High
$6.29
Day's Low
$6.13
Volume
835,237
Avg. Vol
2,094,755
52-wk High
$6.33
52-wk Low
$1.85

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $234.22
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  CPRX.O Industry Sector
P/E (TTM): -- 69.38 32.67
EPS (TTM): -0.20 -- --
ROI: -42.00 8.95 14.48
ROE: -42.26 10.09 15.78

Catalyst Pharma sues FDA over approval of cheaper rival drug

Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.

Jun 12 2019

UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug

June 12 Catalyst Pharmaceuticals Inc, which has come under fire for the high price tag on its rare disease drug, on Wednesday sued the U.S. Food and Drug Administration to challenge the recent approval of a lower-cost rival drug.

Jun 12 2019

Catalyst Pharma files lawsuit against U.S. FDA on Jacobus Pharma drug approval

June 12 Catalyst Pharmaceuticals Inc said on Wednesday it has filed a lawsuit against the U.S. Food and Drug Administration, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for a rare neuromuscular disease.

Jun 12 2019

UPDATE 1-U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

Feb 28 U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

Feb 28 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates